90281     |Immune globulin (Ig), human, for intramuscular use||IG|86        ||2024/06/13|169       
90283     |Immune globulin (IgIV), human, for intravenous use||IGIV|87        ||2024/06/13|170       
90287     |Botulinum antitoxin, equine, any route||botulinum antitoxin|27        ||2024/06/13|171       
90291     |Cytomegalovirus immune globulin (CMV-IgIV), human, for intravenous use||CMVIG|29        ||2024/06/13|172       
90296     |Diphtheria antitoxin, equine, any route||diphtheria antitoxin|12        ||2024/06/13|173       
90371     |Hepatitis B immune globulin (HBIg), human, for intramuscular use||HBIG|30        ||2024/06/13|174       
90375     |Rabies immune globulin (RIg), human, for intramuscular and/or subcutaneous use||RIG|34        ||2024/06/13|175       
90376     |Rabies immune globulin, heat-treated (RIg-HT), human, for intramuscular and/or subcutaneous use||RIG|34        ||2024/06/13|176       
90378     |Respiratory syncytial virus, monoclonal antibody, recombinant, for intramuscular use, 50 mg, each||RSV-MAb|93        ||2024/06/13|177       
90380     |Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use||RSV, mAb, nirsevimab-alip, 0.5 mL, neonate to 24 months|306       |CPT Code to be used for Beyfortus 0.5 mL|2024/06/13|365       
90381     |Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use||RSV, mAb, nirsevimab-alip, 1 mL, neonate to 24 months|307       |CPT Code to be used for Beyfortus 1.0 mL|2024/06/13|366       
90382     |Respiratory syncytial virus, monoclonal antibody, seasonal dose, 0.7 mL, for intramuscular use||RSV, mAb, clesrovimab-cfor, 0.7 mL, neonate and infant, PF|332       ||2025/06/26|          
90389     |Tetanus immune globulin (TIg), human, for intramuscular use||TIG|13        ||2024/06/13|179       
90393     |Vaccinia immune globulin, human, for intramuscular use||vaccinia immune globulin|79        ||2024/06/13|180       
90396     |Varicella-zoster immune globulin, human, for intramuscular use||VZIG|36        ||2024/06/13|150       
90470     |H1N1 immunization administration (intramuscular, intranasal), including counseling when performed||Novel Influenza-H1N1-09, all formulations|128       ||2017/02/28|297       
90476     |Adenovirus vaccine, type 4, live, for oral use||adenovirus, type 4|54        ||2024/06/13|151       
90477     |Adenovirus vaccine, type 7, live, for oral use||adenovirus, type 7|55        ||2024/06/13|152       
90581     |Anthrax vaccine, for subcutaneous or intramuscular use||Anthrax, pre-exposure prophylaxis, post-exposure prophylaxis|24        ||2024/06/13|153       
90581     |Anthrax vaccine, for subcutaneous or intramuscular use||Anthrax, post-exposure prophylaxis|318       ||2024/06/13|153       
90585     |Bacillus Calmette-Guerin vaccine (BCG) for tuberculosis, live, for percutaneous use||BCG|19        ||2024/06/13|154       
90587     |Dengue vaccine, quadrivalent, live, 3 dose schedule, for subcutaneous use||dengue fever tetravalent|56        ||2024/06/13|          
90589     |Chikungunya virus vaccine, live attenuated, for intramuscular use||Chikungunya live attenuated vaccine, 0.5 mL, PF|317       ||2024/06/13|          
90593     |Chikungunya virus vaccine, recombinant, for intramuscular use||Chikungunya, VLP, recombinant, 0.8 mL, PF|329       ||2025/04/15|          
90611     |Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, non-replicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous use||Vaccinia, smallpox monkeypox vaccine live, PF, SQ or ID injection|206       |CPT Code to be used for JYNNEOS vaccine|2024/06/13|356       
90616     |Influenza virus vaccine, trivalent (tIRV), mRNA, 37.5 mcg/0.38 mL dosage, for intramuscular use||Influenza, mRNA, trivalent, PF|338       ||2026/07/07|          
90619     |Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT), for intramuscular use||meningococcal conjugate quadrivalent, MenACWY-TT (MCV4)|203       ||2024/06/13|337       
90620     |Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), for intramuscular use||meningococcal B, OMV|163       ||2026/07/07|314       
90621     |Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2 or 3 dose schedule, for intramuscular use||meningococcal B, recombinant|162       ||2024/06/13|313       
90622     |Vaccinia (smallpox) virus vaccine, live, lyophilized, 0.3 mL dosage, for percutaneous use||Vaccinia (smallpox, monkeypox), live|75        |CPT Code to be used for ACAM2000 vaccine|2024/06/13|357       
90623     |Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y- tetanus toxoid carrier, and Men B-FHbp, for intramuscular use||Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF|316       ||2024/06/13|          
90624     |Meningococcal pentavalent vaccine, Men B-4C recombinant proteins and outer membrane vesicle and conjugated Men A, C, W, Y-diphtheria toxoid carrier, for intramuscular use||Meningococcal oligosaccharide (MenACWY), (MenB), PF|328       ||2024/07/09|          
90625     |Cholera vaccine, live, adult dosage, 1 dose schedule, for oral use||cholera, live attenuated|174       ||2024/06/13|327       
90626     |Tick-borne encephalitis virus vaccine, inactivated; 0.25 mL dosage, for intramuscular use||Tick-borne encephalitis, inactivated, PF, 0.25mL|223       ||2024/06/13|343       
90627     |Tick-borne encephalitis virus vaccine, inactivated; 0.5 mL dosage, for intramuscular use||Tick-borne encephalitis, inactivated, PF, 0.5mL|224       ||2024/06/13|344       
90630     |Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, for intradermal use||influenza, intradermal, quadrivalent, preservative free|166       ||2024/09/24|316       
90632     |Hepatitis A vaccine (HepA), adult dosage, for intramuscular use||Hep A, adult|52        ||2024/06/13|155       
90633     |Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use||Hep A, ped/adol, 2 dose|83        ||2024/06/13|156       
90634     |Hepatitis A vaccine (HepA), pediatric/adolescent dosage-3 dose schedule, for intramuscular use||Hep A, ped/adol, 3 dose|84        ||2024/06/13|157       
90636     |Hepatitis A and hepatitis B vaccine (HepA-HepB), adult dosage, for intramuscular use||Hep A-Hep B|104       ||2024/06/13|158       
90644     |Meningococcal conjugate vaccine, serogroups C & Y and Haemophilus influenzae type b vaccine (Hib-MenCY), 4 dose schedule, when administered to children 6 weeks-18 months of age, for intramuscular use||Meningococcal C/Y-HIB PRP|148       ||2024/06/13|317       
90645     |Hemophilus influenza b vaccine (Hib), HbOC conjugate (4 dose schedule), for intramuscular use||Hib (HbOC)|47        ||2017/02/28|159       
90646     |Hemophilus influenza b vaccine (Hib), PRP-D conjugate, for booster use only, intramuscular use||Hib (PRP-D)|46        ||2017/02/28|160       
90647     |Haemophilus influenzae type b vaccine (Hib), PRP-OMP conjugate, 3 dose schedule, for intramuscular use||Hib (PRP-OMP)|49        ||2024/06/13|161       
90648     |Haemophilus influenzae type b vaccine (Hib), PRP-T conjugate, 4 dose schedule, for intramuscular use||Hib (PRP-T)|48        ||2024/06/13|162       
90649     |Human Papillomavirus vaccine, types 6, 11, 16, 18, quadrivalent (4vHPV), 3 dose schedule, for intramuscular use||HPV, quadrivalent|62        ||2024/06/13|163       
90650     |Human Papillomavirus vaccine, types 16, 18, bivalent (2vHPV), 3 dose schedule, for intramuscular use||HPV, bivalent|118       ||2024/06/13|164       
90651     |Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use||HPV9|165       ||2024/06/13|318       
90653     |Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use||Influenza, adjuvanted, trivalent, PF|168       ||2024/06/13|325       
90654     |Influenza virus vaccine, trivalent (IIV3), split virus, preservative-free, for intradermal use||influenza, seasonal, intradermal, preservative free|144       ||2024/09/24|302       
90656     |Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use||Influenza, split virus, trivalent, PF|140       ||2024/06/13|166       
90657     |Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use||Influenza, split virus, trivalent, preservative|141       ||2024/06/13|167       
90658     |Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use||Influenza, split virus, trivalent, preservative|141       ||2024/06/13|168       
90659     |Influenza virus vaccine, whole virus, for intramuscular or jet injection use||influenza, whole|16        ||2017/02/28|181       
90660     |Influenza virus vaccine, trivalent, live (LAIV3), for intranasal use||Influenza, live, trivalent, intranasal, PF|111       ||2024/06/13|182       
90661     |Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use||Influenza, MDCK, trivalent, PF|153       ||2024/09/24|310       
90661     |Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use||Influenza, MDCK, trivalent, preservative|320       ||2024/09/24|310       
90662     |Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use||Influenza, high-dose, trivalent, PF|135       ||2024/06/13|292       
90662     |Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use||Influenza, high-dose, quadrivalent, PF|197       ||2024/06/13|292       
90663     |Influenza virus vaccine, pandemic formulation, H1N1||Novel Influenza-H1N1-09, all formulations|128       ||2017/02/28|293       
90664     |Influenza virus vaccine, live (LAIV), pandemic formulation, for intranasal use||Novel Influenza-H1N1-09, nasal|125       ||2024/06/13|294       
90665     |Lyme disease vaccine, adult dosage, for intramuscular use||Lyme disease|66        ||2017/02/28|183       
90666     |Influenza virus vaccine (IIV), pandemic formulation, split virus, preservative free, for intramuscular use||Novel influenza-H1N1-09, preservative-free|126       ||2024/06/13|300       
90668     |Influenza virus vaccine (IIV), pandemic formulation, split virus, for intramuscular use||Novel influenza-H1N1-09|127       ||2024/06/13|296       
90669     |Pneumococcal conjugate vaccine, 7 valent, for intramuscular use||pneumococcal conjugate PCV 7|100       ||2017/02/28|184       
90670     |Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use||Pneumococcal conjugate PCV 13|133       ||2024/06/13|185       
90671     |Pneumococcal conjugate vaccine, 15 valent (PCV15), for intramuscular use||Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF|215       ||2024/06/13|345       
90672     |Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use||Influenza, live, quadrivalent, intranasal|149       ||2024/06/13|319       
90673     |Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use||Influenza, recombinant, trivalent, PF|155       ||2024/06/13|311       
90674     |Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use||Influenza, MDCK, quadrivalent, PF|171       ||2024/06/13|326       
90675     |Rabies vaccine, for intramuscular use||Rabies - IM Diploid cell culture|175       ||2024/06/13|186       
90675     |Rabies vaccine, for intramuscular use||Rabies - IM fibroblast culture|176       ||2024/06/13|186       
90676     |Rabies vaccine, for intradermal use||rabies, intradermal injection|40        ||2024/06/13|187       
90677     |Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use||Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF|216       ||2024/06/13|346       
90678     |Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use||RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF|305       |CPT Code to be used for ABRYSVO|2024/06/13|367       
90679     |Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use||RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF|303       |CPT Code to be Used for Arexvy|2024/06/13|364       
90680     |Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use||rotavirus, pentavalent|116       ||2024/06/13|188       
90681     |Rotavirus vaccine, human, attenuated (RV1), 2 dose schedule, live, for oral use||rotavirus, monovalent|119       ||2024/06/13|189       
90682     |Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use||Influenza, recombinant, quadrivalent, PF|185       ||2024/06/13|332       
90683     |Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use||RSV, mRNA, injectable, PF|326       ||2024/06/13|          
90684     |Pneumococcal conjugate vaccine, 21 valent (PCV21), for intramuscular use||Pneumococcal conjugate PCV21, polysaccharide CRM197 conjugate, PF|327       ||2024/07/09|          
90685     |Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use||Influenza, injectable,quadrivalent, preservative free, pediatric|161       ||2024/06/13|305       
90686     |Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use||Influenza, split virus, quadrivalent, PF|150       ||2024/06/13|306       
90687     |Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use||Influenza, split virus, quadrivalent, preservative|158       ||2024/06/13|312       
90688     |Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use||Influenza, split virus, quadrivalent, preservative|158       ||2024/06/13|308       
90690     |Typhoid vaccine, live, oral||typhoid, oral|25        ||2024/06/13|190       
90691     |Typhoid vaccine, Vi capsular polysaccharide (ViCPs), for intramuscular use||typhoid, ViCPs|101       ||2024/06/13|191       
90692     |Typhoid vaccine, heat- and phenol-inactivated (H-P), for subcutaneous or intradermal use||typhoid, parenteral|41        ||2017/02/28|192       
90693     |Typhoid vaccine, acetone-killed, dried (AKD), for subcutaneous use (U.S. military)||typhoid, parenteral, AKD (U.S. military)|53        ||2017/02/28|193       
90694     |Influenza virus vaccine, quadrivalent (aIIV4), inactivated, adjuvanted, preservative free, 0.5 mL dosage, for intramuscular use||Influenza, adjuvanted, quadrivalent, PF|205       ||2024/06/13|336       
90696     |Diphtheria, tetanus toxoids, acellular pertussis vaccine and inactivated poliovirus vaccine (DTaP-IPV), when administered to children 4 through 6 years of age, for intramuscular use||DTaP-IPV|130       ||2024/06/13|194       
90697     |Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP-IPV-Hib-HepB), for intramuscular use||DTaP,IPV,Hib,HepB|146       ||2024/06/13|328       
90698     |Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenzae type b, and inactivated poliovirus vaccine, (DTaP-IPV/Hib), for intramuscular use||DTaP-Hib-IPV|120       ||2024/06/13|195       
90700     |Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than 7 years, for intramuscular use||DTaP, 5 pertussis antigens|106       ||2024/06/13|196       
90700     |Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than 7 years, for intramuscular use||DTaP|20        ||2024/06/13|196       
90701     |Diphtheria, tetanus toxoids, and whole cell pertussis vaccine (DTP), for intramuscular use||DTP|01        ||2017/02/28|197       
90702     |Diphtheria and tetanus toxoids adsorbed (DT) when administered to individuals younger than 7 years, for intramuscular use||DT (pediatric)|28        ||2024/06/13|198       
90703     |Tetanus toxoid adsorbed, for intramuscular use||tetanus toxoid, adsorbed|35        ||2017/02/28|199       
90704     |Mumps virus vaccine, live, for subcutaneous use||mumps|07        ||2017/02/28|200       
90705     |Measles virus vaccine, live, for subcutaneous use||measles|05        ||2017/02/28|201       
90706     |Rubella virus vaccine, live, for subcutaneous use||rubella|06        ||2017/02/28|202       
90707     |Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use||MMR|03        ||2024/06/13|203       
90708     |Measles and rubella virus vaccine, live, for subcutaneous use||M/R|04        ||2017/02/28|204       
90710     |Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use||MMRV|94        ||2024/06/13|205       
90713     |Poliovirus vaccine, inactivated (IPV), for subcutaneous or intramuscular use||IPV|10        ||2024/06/13|207       
90714     |Tetanus and diphtheria toxoids adsorbed (Td), preservative free, when administered to individuals 7 years or older, for intramuscular use||Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed|09        |Beginning in 2005, this CPT code maps to TD preservative free. Remapped to CVX code 09 10/2021 to support active products mapped to that code.|2024/06/13|208       
90714     |Tetanus and diphtheria toxoids adsorbed (Td), preservative free, when administered to individuals 7 years or older, for intramuscular use||Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbed|113       |Beginning in 2005, this CPT code maps to TD preservative free. Remapped to CVX code 09 10/2021 to support active products mapped to that code.|2024/06/13|208       
90715     |Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use||Tdap|115       ||2024/06/13|210       
90716     |Varicella virus vaccine (VAR), live, for subcutaneous use||varicella|21        ||2024/06/13|211       
90717     |Yellow fever vaccine, live, for subcutaneous use||yellow fever live|37        ||2024/06/13|212       
90717     |Yellow fever vaccine, live, for subcutaneous use||Yellow fever vaccine live - alt|183       ||2024/06/13|212       
90720     |Diphtheria, tetanus toxoids, and whole cell pertussis vaccine and Hemophilus influenza B vaccine (DTP-Hib), for intramuscular use||DTP-Hib|22        ||2017/02/28|214       
90721     |Diphtheria, tetanus toxoids, and acellular pertussis vaccine and Hemophilus influenza B vaccine (DTaP/Hib), for intramuscular use||DTaP-Hib|50        ||2017/02/28|215       
90723     |Diphtheria, tetanus toxoids, acellular pertussis vaccine, hepatitis B, and inactivated poliovirus vaccine (DTaP-HepB-IPV), for intramuscular use||DTaP-Hep B-IPV|110       ||2024/06/13|216       
90727     |Plague vaccine, for intramuscular use||plague|23        ||2017/02/28|220       
90728     |BCG vaccine||BCG|19        ||2017/03/03|221       
90732     |Pneumococcal polysaccharide vaccine, 23-valent (PPSV23), adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use||pneumococcal polysaccharide PPV23|33        ||2024/06/13|224       
90733     |Meningococcal polysaccharide vaccine, serogroups A, C, Y, W-135, quadrivalent (MPSV4), for subcutaneous use||meningococcal MPSV4|32        ||2024/06/13|225       
90734     |Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier (MenACWY-D) or CRM197 carrier (MenACWY-CRM), for intramuscular use||meningococcal MCV4P|114       ||2024/06/13|226       
90734     |Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier (MenACWY-D) or CRM197 carrier (MenACWY-CRM), for intramuscular use||Meningococcal MCV4O|136       ||2024/06/13|226       
90735     |Japanese encephalitis virus vaccine, for subcutaneous use||Japanese encephalitis SC|39        ||2017/02/28|227       
90736     |Zoster (shingles) vaccine (HZV), live, for subcutaneous injection||zoster live|121       ||2024/06/13|228       
90737     |Hemophilus influenza B||Hib, unspecified formulation|17        ||2017/03/03|229       
90738     |Japanese encephalitis virus vaccine, inactivated, for intramuscular use||Japanese Encephalitis IM|134       ||2024/06/13|230       
90739     |Hepatitis B vaccine (HepB), CpG-adjuvanted, adult dosage, 2 dose or 4 dose schedule, for intramuscular use||HepB-CpG|189       ||2024/06/13|324       
90740     |Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 3 dose schedule, for intramuscular use||Hep B, high-dosage, dialysis or IC|44        ||2024/06/13|231       
90741     |Immunization, passive; immune serum globulin, human (ISG)||IG, unspecified formulation|14        ||2017/03/03|232       
90743     |Hepatitis B vaccine (HepB), adolescent, 2 dose schedule, for intramuscular use||Hep B, adult|43        ||2024/06/13|233       
90743     |Hepatitis B vaccine (HepB), adolescent, 2 dose schedule, for intramuscular use||Hep B, adolescent or pediatric|08        ||2024/06/13|233       
90744     |Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use||Hep B, adolescent or pediatric|08        ||2024/06/13|234       
90745     |Hepatitis B vaccine, adolescent/high risk infant dosage, for intramuscular use||Hep B, adolescent/high risk infant|42        ||2017/03/03|235       
90746     |Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use||Hep B, adult|43        ||2024/06/13|236       
90747     |Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 4 dose schedule, for intramuscular use||Hep B, high-dosage, dialysis or IC|44        ||2024/12/11|237       
90748     |Hepatitis B and Haemophilus influenzae type b vaccine (Hib-HepB), for intramuscular use||Hib-Hep B|51        ||2024/06/13|238       
90750     |Zoster (shingles) vaccine (HZV), recombinant, subunit, adjuvanted, for intramuscular use||zoster recombinant|187       ||2024/06/13|334       
90756     |Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use||Influenza, MDCK, quadrivalent, preservative|186       |Effective 1/1/2018|2024/06/13|333       
90758     |Zaire ebolavirus vaccine, live, for intramuscular use||Ebola Zaire vaccine, live, recombinant, 1mL dose|204       ||2024/06/13|347       
90759     |Hepatitis B vaccine (HepB), 3-antigen (S, Pre-S1, Pre-S2), 10 mcg dosage, 3 dose schedule, for intramuscular use||HepB recombinant, 3-antigen, Al(OH)3|220       ||2024/06/13|348       
91300     |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use||COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose|208       |COVID-19 Vaccine - EUA authorized 12/11/2020|2024/06/13|338       
91301     |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use||COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose|207       |COVID-19 Vaccine - BLA Licensed and EUA authorized|2024/06/13|339       
91302     |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5 mL dosage, for intramuscular use||COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL|210       |COVID-19 Vaccine - EUA submission withdrawn |2024/06/13|340       
91303     |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5 mL dosage, for intramuscular use||COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL|212       |COVID-19 Vaccine - EUA authorized 2/27/2021|2024/06/13|341       
91304     |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5 mL dosage, for intramuscular use||COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL|211       |Original and Fall COVID-19 vaccine starting 2023|2024/09/24|342       
91304     |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5 mL dosage, for intramuscular use||COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL|313       |Original and Fall COVID-19 vaccine starting 2023|2024/09/24|342       
91305     |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use||COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose|217       |COVID-19 Vaccine - EUA authorized for primary series and IC, EUA rescinded 8/31/202 for monovalent boosters  |2024/06/13|349       
91306     |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use||COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose|207       |COVID-19 Vaccine - EUA authorization rescinded 8/31/2022 for adult monovalent booster dose|2024/06/13|350       
91307     |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use||COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose|218       |COVID-19 Vaccine - EUA authorized, pediatric 5 yrs through 11 yrs dose requires dilution|2024/06/13|351       
91308     |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use||COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose|219       |COVID-19 Vaccine - EUA authorized for children under 5 yrs|2024/06/13|352       
91309     |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use||COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose|221       |COVID-19 Vaccine - EUA authorized for pediatric, EUA rescinded 8/31/2022 for adult monovalent booster dose|2024/06/13|353       
91310     |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use||COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 5mcg/0.5mL|225       |COVID-19 Vaccine - Potential EUA authorization booster dose|2024/06/13|355       
91311     |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use||COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose|228       |COVID-19 Vaccine - EUA authorized for ages 6 mo through 5 yrs|2024/06/13|354       
91312     |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use||COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose|300       |COVID-19 Vaccine - EUA authorized 8/31/2022 bivalent booster ages 12+ yrs|2024/06/13|361       
91313     |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use||COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose|229       |COVID-19 Vaccine - EUA authorized 8/31/2022 bivalent booster for ages 18+ yrs, potential EUA ages 6 yrs through 17 yrs|2024/06/13|360       
91314     |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use||COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose|229       |COVID-19 Vaccine - EUA authorized 8/31/2022 bivalent booster for ages 6 yrs through 11 yrs|2024/06/13|359       
91315     |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use||COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL dose|301       |COVID-19 Vaccine - Potential EUA authorization bivalent booster for ages 5 yrs through 11 yrs|2024/06/13|358       
91316     |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use||COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL|230       |COVID-19 Vaccine - EUA authorized 12/8/2022  bivalent booster (Moderna) for ages 6 mo through 5 yrs|2024/06/13|362       
91317     |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use||COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose|302       |COVID-19 Vaccine - EUA authorized 12/8/2022  bivalent vaccine (Pfizer) for ages 6 mo through 4 yrs|2024/06/13|363       
91318     |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use||COVID-19, mRNA, LNP-S, PF, tris-sucrose, 3 mcg/0.3 mL|308       |Fall COVID-19 vaccine starting 2023|2024/09/24|368       
91319     |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use||COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mL|310       |Fall COVID-19 vaccine starting 2023|2024/09/24|369       
91320     |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use||COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL|309       |Fall COVID-19 vaccine starting 2023|2024/09/24|370       
91321     |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use||COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL|311       |Fall COVID-19 vaccine starting 2023|2024/09/24|371       
91322     |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use||COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL|312       |Fall COVID-19 vaccine starting 2023|2024/09/24|372       
91323     |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 10 mcg/0.2 mL dosage, for intramuscular use||COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL|334       ||2025/04/15|          
